elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Erlotinib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Erlotinib
RIS
0.001
(Research Intensity Score)
Papers
149
Top papers
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2023 · 681 citations
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · 151 citations
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
2021 · 640 citations
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
2019 · 1112 citations
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
2025 · 27 citations
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
2023 · 73 citations
Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development
2025 · 18 citations
Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy
2024 · 32 citations
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
2018 · 293 citations
Newest papers
Multifunctional Hybrid Nano-Platform for Co-Delivery of Erlotinib and Silibinin: A Nanotherapeutic Strategy Against Triple-Negative Breast Cancer
2026
Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI–treated NSCLC: a cross-database real-world study
2026
Afatinib-Induced Acneiform Eruption in EGFR Exon 21 L858R-Mutant Stage IVA Lung Adenosquamous Carcinoma: Dermoscopy-Supported Diagnosis and Complete Resolution Fifteen Days After Drug Withdrawal
2026
Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination
2026
PandaMap: A Python Package for Comprehensive Visualization of Protein-Ligand Interaction Networks
2026
Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer
2026
Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer
2026
Ultrasensitive Optoelectronic Quantification of Erlotinib in Metastatic Pancreatic Adenocarcinoma Based on BiOBr/Bi2Te3 Heterojunction for Therapeutic Efficacy Assessment
2026
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
2025 · 27 citations
Browse all papers →
Erlotinib's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Erlotinib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link